Skip to Content


In the US, Rilonacept (rilonacept systemic) is a member of the drug class interleukin inhibitors and is used to treat Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Gout and Muckle Wells Syndrome.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Category


Chemical Names

[653-Glycine][human interleukin-1 receptor acceβory protein-(1-339)-peptide (extracellular domain fragment) fusion protein withuman type 1 interleukin-1 receptor-(5-316)-peptide (extracellulardomain fragment) fusion protein wit human immunoglobulin G1-(22 (WHO)

Interleukin 1 receptor acceβory protein (human extracellular domain fragment) fusion protein wit type I interleukin 1 receptor (human extracellular domain fragment) fusion protein wit immunoglobulin G1 (human Fc fragment), homodimer (USAN)

Foreign Names

  • Rilonaceptum (Latin)
  • Rilonacept (German)
  • Rilonacept (French)
  • Rilonacept (Spanish)

Generic Names

  • Rilonacept (OS: USAN)
  • Cytokine Trap (IS)
  • IL-1 Trap (IS: Regeneron)
  • Interleukin-1 Trap (IS)
  • RGN-303 (IS)
  • UNII-8K80YB5GMG (IS)

Brand Names


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.